极早产儿早期氨基酸与2岁时神经功能障碍
这项多中心、平行组、双盲、随机、安慰剂对照试验纳入出生体重<1000 g的极低出生体重儿434例(每组217例),在常规营养基础上随机接受每日氨基酸1 g或安慰剂,持续出生后5天。主要终点2岁(校正胎龄)无神经功能障碍生存率干预组47.8%(97/203)vs 安慰剂组49.8%(102/205),校正相对危险度0.95(95%CI 0.79–1.14;P=0.56)。中重度神经功能障碍干预组16.5%(27例)vs 安慰剂组8.6%(14例),校正相对危险度1.95(95%CI 1.09–3.48);动脉导管未闭干预组多于安慰剂组(校正相对危险度1.65;95%CI 1.11–2.46)。作者结论认为,极低出生体重儿出生后5天每日额外静脉补充氨基酸1 g未增加2岁时无神经功能障碍生存人数。
要点
- 极低出生体重儿(<1000 g)出生后5天每日额外静脉氨基酸1 g,2岁无神经功能障碍生存率47.8%(97/203)vs 安慰剂49.8%(102/205),校正RR 0.95(95%CI 0.79–1.14;P=0.56)。
- 中重度神经功能障碍干预组16.5%(27例)vs 安慰剂组8.6%(14例),校正RR 1.95(95%CI 1.09–3.48)。
- 动脉导管未闭干预组多于安慰剂组(校正RR 1.65;95%CI 1.11–2.46)。
- 事后分析再喂养综合征干预组42/172 vs 安慰剂组26/166(校正RR 1.64;95%CI 1.09–2.47)。
- 2岁前死亡干预组18.0%(39/217)vs 安慰剂组19.4%(42/217),校正RR 0.93(95%CI 0.63–1.36);神经功能障碍干预组40.9%(67/164)vs 安慰剂组37.4%(61/163),校正RR 1.16(95%CI 0.90–1.50)。
适用人群与场景
- 出生体重<1000 g的极低出生体重儿,在8个新生儿重症监护病房(NICU)纳入。
处置流程与药物剂量
- 干预组在常规营养基础上接受氨基酸每日1 g,出生后前5天给药;对照组接受安慰剂。
研究设计与关键结果
- 多中心、平行组、双盲、随机、安慰剂对照试验,纳入434例(每组217例),8个NICU。
- 主要终点2岁(校正胎龄)无神经功能障碍生存率:干预组47.8%(97/203)vs 安慰剂组49.8%(102/205),校正相对危险度0.95(95%CI 0.79–1.14;P=0.56)。
- 2岁前死亡:干预组18.0%(39/217)vs 安慰剂组19.4%(42/217),校正相对危险度0.93(95%CI 0.63–1.36)。
- 神经功能障碍:干预组40.9%(67/164)vs 安慰剂组37.4%(61/163),校正相对危险度1.16(95%CI 0.90–1.50)。
- 中重度神经功能障碍:干预组16.5%(27例)vs 安慰剂组8.6%(14例),校正相对危险度1.95(95%CI 1.09–3.48)。
- 动脉导管未闭:干预组多于安慰剂组(校正相对危险度1.65;95%CI 1.11–2.46)。
- 事后分析再喂养综合征:干预组42/172 vs 安慰剂组26/166(校正相对危险度1.64;95%CI 1.09–2.47)。
- 严重不良事件8例。
证据类型、等级与局限
- 证据类型:多中心、平行组、双盲、随机、安慰剂对照试验。
- 资助:新西兰健康研究委员会等;ProVIDe试验,澳大利亚新西兰临床试验注册号ACTRN12612001084875。
- 局限:原文未报告局限性
对床旁实践的改变
- 作者结论认为,极低出生体重儿出生后5天每日额外静脉补充氨基酸1 g未增加2岁时无神经功能障碍生存人数。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether higher parenteral amino acid intake improves outcomes in infants with extremely low birth weight is unclear.
METHODS: In this multicenter, parallel-group, double-blind, randomized, placebo-controlled trial, we assigned infants with birth weights of less than 1000 g at 8 neonatal intensive care units to receive amino acids at a dose of 1 g per day (intervention group) or placebo in addition to usual nutrition for the first 5 days after birth. The primary outcome was survival free from neurodisability as assessed with the Bayley Scales of Infant and Toddler Development and neurologic examination at 2 years, corrected for gestational age at birth. Secondary outcomes were the components of the primary outcome as well as the presence or absence of neonatal disorders, the rate of growth, and nutritional intake.
RESULTS: We enrolled 434 infants (217 per group) in this trial. Survival free from neurodisability was observed in 97 of 203 children (47.8%) in the intervention group and in 102 of 205 (49.8%) in the placebo group (adjusted relative risk, 0.95; 95% confidence interval [CI], 0.79 to 1.14; P = 0.56). Death before the age of 2 years occurred in 39 of 217 children (18.0%) in the intervention group and 42 of 217 (19.4%) in the placebo group (adjusted relative risk, 0.93; 95% CI, 0.63 to 1.36); neurodisability occurred in 67 of 164 children (40.9%) in the intervention group and 61 of 163 (37.4%) in the placebo group (adjusted relative risk, 1.16; 95% CI, 0.90 to 1.50). Neurodisability was moderate to severe in 27 children (16.5%) in the intervention group and 14 (8.6%) in the placebo group (adjusted relative risk, 1.95; 95% CI, 1.09 to 3.48). More children in the intervention group than in the placebo group had patent ductus arteriosus (adjusted relative risk, 1.65; 95% CI, 1.11 to 2.46). In a post hoc analysis, refeeding syndrome occurred in 42 of 172 children in the intervention group and 26 of 166 in the placebo group (adjusted relative risk, 1.64; 95% CI, 1.09 to 2.47). Eight serious adverse events occurred.
CONCLUSIONS: In infants with extremely low birth weight, extra parenteral amino acids at a dose of 1 g per day for 5 days after birth did not increase the number who survived free from neurodisability at 2 years. (Funded by the New Zealand Health Research Council and others; ProVIDe Australian New Zealand Clinical Trials Registry number, ACTRN12612001084875.).
参考来源
- Bloomfield FH, Jiang Y, Harding JE, et al. Early Amino Acids in Extremely Preterm Infants and Neurodisability at 2 Years. N Engl J Med. 2022. PMID: 36322845. doi:10.1056/NEJMoa2204886
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。